• 1
    Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 153.
  • 2
    Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695703.
  • 3
    Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 26573.
  • 4
    Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 104150.
  • 5
    Park BJ, Pappas PG, Wannemuehler KA et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis 2011; 17: 185564.
  • 6
    Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091100.
  • 7
    Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010; 50: 40515.
  • 8
    Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients – a meta-analysis of randomized-controlled clinical trials. Cancer 2002; 94: 323046.
  • 9
    Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91: 9869.
  • 10
    Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009; 48: 103341.
  • 11
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 13363.
  • 12
    Thors VS, Bierings MB, Melchers WJ, Verweij PE, Wolfs TF. Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy. Pediatr Infect Dis J 2011; 30: 26870.
  • 13
    Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 11: e219.
  • 14
    Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 11239.
  • 15
    Dodds-Ashley ES, Lewis RE, Lewis JS 2nd, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43(Suppl. 1): S2839.
  • 16
    De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 181321.
  • 17
    Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 64450.
  • 18
    Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infection 2010; 61: 25965.
  • 19
    Shojania KG, Burton EC. The vanishing nonforensic autopsy. N Engl J Med 2008; 358: 8735.
  • 20
    Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De la Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003; 82: 802.
  • 21
    Tarrand JJ, Han XY, Kontoyiannis DP, May GS. Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery. J Clin Microbiol 2005; 43: 3826.
  • 22
    Kontoyiannis DP, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of Zygomycetes under physiologic temperature conditions. Am J Clin Pathol 2007; 127: 20812.
  • 23
    Shojania KG, Burton EC, McDonald KM, Goldman L. Changes in rates of autopsy-detected diagnostic errors over time: a systematic review. JAMA 2003; 289: 284956.
  • 24
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 181326.
  • 25
    Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol 2011; 38: 196214.
  • 26
    Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494503.
  • 27
    Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol 2009; 47: S27181.
  • 28
    Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15(Suppl. 5): 937.
  • 29
    Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 2332.
  • 30
    Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 474552.
  • 31
    Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 24939.
  • 32
    Kontoyiannis DP, Reddy BT, Torres HA et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34: 4003.
  • 33
    Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65: 2935.
  • 34
    Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 2008; 52: 41813.